Literature DB >> 21483017

Genetic testing for lung cancer: reflex versus clinical selection.

Paul A Bunn, Robert C Doebele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21483017      PMCID： PMC4819165          DOI： 10.1200/JCO.2010.34.1974

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  29 in total

1.  Missense mutations of the BRAF gene in human lung adenocarcinoma.

Authors:  Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Authors:  Sai-Hong Ignatius Ou; Lyudmila Bazhenova; D Ross Camidge; Benjamin J Solomon; June Herman; Tatiana Kain; Yung-Jue Bang; Eunice L Kwak; Alice T Shaw; Ravi Salgia; Robert G Maki; Jeffrey W Clark; Keith D Wilner; A John Iafrate
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

3.  Uncommon V599E BRAF mutations in Japanese patients with lung cancer.

Authors:  Hidefumi Sasaki; Osamu Kawano; Katsuhiko Endo; Eriko Suzuki; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  J Surg Res       Date:  2005-12-27       Impact factor: 2.192

4.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

7.  Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Authors:  D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

8.  Genetic predictors of MEK dependence in non-small cell lung cancer.

Authors:  Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

Authors:  Samuel A Yousem; Marina Nikiforova; Yuri Nikiforov
Journal:  Am J Surg Pathol       Date:  2008-09       Impact factor: 6.394

10.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701
View more
  4 in total

1.  Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Authors:  Dong Xie; Mark S Allen; Randolph Marks; Gening Jiang; Zhifu Sun; Frances Nichols; Mingrui Zhang; Chang Chen; Marie-Christine Aubry; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Dennis Wigle; Julian Molina; Claude Deschamps; Ping Yang
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

Review 2.  Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.

Authors:  Yue Yu; Jie He
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

3.  Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Authors:  Benjamin P Levy; Marc D Chioda; Dana Herndon; John W Longshore; Mohamed Mohamed; Sai-Hong Ignatius Ou; Craig Reynolds; Jaspal Singh; Ignacio I Wistuba; Paul A Bunn; Fred R Hirsch
Journal:  Oncologist       Date:  2015-09-01

4.  Construction of a Nomogram for Predicting Survival in Elderly Patients With Lung Adenocarcinoma: A Retrospective Cohort Study.

Authors:  Haisheng You; Mengmeng Teng; Chun Xia Gao; Bo Yang; Sasa Hu; Taotao Wang; Yalin Dong; Siying Chen
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.